This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Khan, A. A.
Right arrow Articles by Remington, J. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Khan, A. A.
Right arrow Articles by Remington, J. S.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, August 1999, p. 2043-2045, Vol. 43, No. 8
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Quinupristin-Dalfopristin Is Active against Toxoplasma gondii

Anis A. Khan,1,2 Teri R. Slifer,1 Fausto G. Araujo,1 and Jack S. Remington1,2,*

Department of Infectious Diseases, Research Institute, Palo Alto Medical Foundation, Palo Alto, California 94301,1 and Department of Infectious Disease and Geographic Medicine, Stanford University School of Medicine, Stanford, California 943052

Received 5 February 1999/Returned for modification 20 April 1999/Accepted 12 May 1999

Synercid and each of its components (quinupristin and dalfopristin) were examined for their activities against Toxoplasma gondii. In vitro, intracellular replication of tachyzoites was inhibited by synercid and each of its two components. The 50% inhibitory concentrations of synercid, quinupristin, and dalfopristin were 1.6, 2.7, and 6.3 µg/ml, respectively. Thus, synercid was markedly more active than its components. Treatment of acutely infected mice with 100 or 200 mg of synercid per kg of body weight per day administered intraperitoneally for 10 days resulted in survival of 50% (P = 0.0002) and 100% (P < 0.0001) of infected mice, respectively, whereas all control mice died by day 18. In contrast, treatment with 200 mg of either quinupristin and dalfopristin per kg per day alone resulted in only 20% survival; treatment with 50 mg of either drug per kg per day resulted only in the prolongation of time to death. These results suggest that synercid may be useful for treatment of toxoplasmosis in humans.

* Corresponding author. Mailing address: Department of Immunology and Infectious Diseases, Research Institute, Palo Alto Medical Foundation, 860 Bryant St., Palo Alto, CA 94301. Phone: (650) 853-6061. Fax: (650) 329-9853.

Antimicrobial Agents and Chemotherapy, August 1999, p. 2043-2045, Vol. 43, No. 8
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Butaye, P., Devriese, L. A., Haesebrouck, F. (2003). Antimicrobial Growth Promoters Used in Animal Feed: Effects of Less Well Known Antibiotics on Gram-Positive Bacteria. Clin. Microbiol. Rev. 16: 175-188 [Abstract] [Full Text]  
  • Walzer, P. D., Ashbaugh, A., Collins, M., Cushion, M. T. (2001). In Vitro and In Vivo Effects of Quinupristin-Dalfopristin against Pneumocystis carinii. Antimicrob. Agents Chemother. 45: 3234-3237 [Abstract] [Full Text]  
  • Khan, A. A., Araujo, F. G., Craft, J. C., Remington, J. S. (2000). Ketolide ABT-773 is active against Toxoplasma gondii. J Antimicrob Chemother 46: 489-492 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»